Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 11/20 | 0.59 |
| ▸ | UTS2R | Q9UKP6 | 8/20 | 0.54 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.48 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.47 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2471256 | 0.92 | UTS2R (0.58) | HDAC1UTS2RHDAC2HDAC3NCOR2 | |
| SCHEMBL2480482 | 0.91 | UTS2R (0.55) | HDAC1UTS2RROCK2ROCK1HDAC2 | |
| SCHEMBL2474090 | 0.89 | UTS2R (0.52) | HDAC1UTS2RHDAC2HDAC3NCOR2 | |
| SCHEMBL2474114 | 0.89 | UTS2R (0.54) | HDAC1UTS2R | |
| SCHEMBL2504353 | 0.89 | UTS2R (0.65) | HDAC1UTS2RHDAC2HDAC3NCOR2 | |
| SCHEMBL2478630 | 0.86 | HDAC1 (0.56) | HDAC1UTS2RHDAC2HDAC3NCOR2 | |
| SCHEMBL3832758 | 0.86 | UTS2R (0.49) | HDAC1UTS2RHDAC2HDAC3NCOR2 | |
| SCHEMBL3834409 | 0.86 | UTS2R (0.49) | HDAC1UTS2RHDAC2HDAC3NCOR2 | |
| SCHEMBL2476211 | 0.85 | HDAC1 (0.56) | HDAC1HDAC2HDAC3NCOR2 | |
| SCHEMBL2476829 | 0.85 | UTS2R (0.49) | HDAC1UTS2RHDAC2HDAC3NCOR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8076332-B2 | N- (2-aminophenyl) benzamide derivative having urea structure | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-12-13 | — | — | US | disclosed |
| US-20090306077-A1 | NOVEL N- (2-AMINOPHENYL) BENZAMIDE DERIVATIVE HAVING UREA STRUCTURE | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2009-12-10 | — | — | US | disclosed |
| EP-2107052-A1 | NOVEL N-(2-AMINOPHENYL)BENZAMIDE DERIVATIVE HAVING AN UREA STRUCTURE | Santen Pharmaceutical Co., Ltd (JP) | 2009-10-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306077-A1 | NOVEL N- (2-AMINOPHENYL) BENZAMIDE DERIVATIVE HAVING UREA STRUCTURE | UACA, SLC14A1, ARG2 | HDAC1 200/4885UTS2R 11/4885ROCK2 499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.